PARP1 and glioblastoma: (172) explored the radiosensitivity of glioblastoma cells and found that PARP inhibitors had the most significant radiosensitizing effect on S-phase glioblastoma cells (SER50 = 1.60) compared with G1-phase (SER50 = 1.27) and G2-phase (SER50 = 1.33) glioblastoma cells.